Solid Biosciences' SGT-003 receives rare pediatric disease designation
Solid Biosciences has received the US FDA rare pediatric disease designation for its gene therapy candidate for Duchenne, SGT-003.
Bo Cumbo News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Bo Cumbo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Bo Cumbo Today - Breaking & Trending Today
Solid Biosciences Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Gene Therapy SGT-003
– Next-generation gene transfer therapy to treat Duchenne receives FDA Fast Track Designation – CHARLESTOWN, Mass., Dec. 07, 2023 -- Solid Biosciences Inc. , a life sciences company...
Source: marketscreener.com
What's Going On With Solid Biosciences Stock Today? - Solid Biosciences (NASDAQ:SLDB)
Solid Biosciences Inc. (NASDAQ: SLDB) shares traded higher on Thursday. The company announced that it received Fast Track Designation from the U.S.
Source: benzinga.com
Solid Up 27% On Receiving FDA IND For SGT-003
Shares of Solid Biosciences Inc. (SLDB) are up 27% on Wednesday following the announcement of FDA clearance of its Investigational New Drug (IND) application for SGT-003, which is the company's latest gene therapy candidate for Duchenne Muscular Dystrophy (Duchenne).
Source: rttnews.com
Why Solid Biosciences Stock Is Climbing Today - Solid Biosciences (NASDAQ:SLDB)
Solid Biosciences Inc.
Source: benzinga.com